subsidiaries have the revenues from medical treatment of 899.25 million baht, which is a 15.55 % increase from the previous year. The revenues can from the two hospitals are broken down as follows

same period previous year is decrease of Baht 30.90 million or 66.04% due to the company recognized the share of loss from investment in an associated company in the amount of Baht 33.08 million. The

of service 1.56 2.26 -0.69 -30.97% Total cost 2,007.11 1,786.69 220.43 12.34% Selling and administrative expense 534.91 458.92 75.99 16.56% Share of profit from investment in associates 43.08 63.12

-9.9 -24.7% Share of profit from investment in associates 126.8 174.8 -48.0 -27.5% Net Profit 999.3 903.2 96.1 10.6% Million Baht Increase (Decrease) The operating result of the Company for FY 2019/2020

same period of last year mainly due to lower aluminium prices.However, when comparing with previous quarter,it was increased 10.5% 2. Cost of sales was 431.57 million Baht or 107.58% of sales which

the second quarter of the year 2020 (QoQ) at Baht 152 Million, net profit increased by Baht 670 Million or 440.8 percent. However, when compared to net profit of the same quarter of the previous year

) SHARE OF LOSS OF INVESTMENT IN JOINT VENTURES ON EQUITY METHOD (0.57) (4.39) - - (0.57) (4.39) INCOME BEFORE TAX 4.51 12.28 6.25 84.10 10.76 96.38 INCOME TAX INCOME 0.56 0.39 - - 0.56 0.39 NET PROFIT FOR

EFORL and its subsidiaries in Q3/2017 was THB 802 million decreased by 6% compared to the same period at the previous year, increasing 14% compared to Q2/2017. It derived from increasing in sales of THB

previous year. This came from decreasing in services revenue whereas sales revenues from medical devices still increased. Revenues from sales and services of EFORL and its subsidiaries in Q3/2018 increased

same period of previous year of Baht 0.02 per share or 4.65 percent, due to the increase in net profit of 2.73 percent. - 4 - EBITDA The Corporate Group’s EBITDA of year 2018 was Baht 767.99 million, a